To fully appreciate how quickly molecular analysis has transformed evaluation and treatment decisions in acute myeloid leukemia (AML), we need look no further than the seminal article by JP Patel et al. published in 2012 in The New England Journal of Medicine concerning the…
Abstract Developing chimeric antigen receptor (CAR) T cells for acute myeloid leukemia (AML) has been challenging due to a lack of known AML-associated antigens that spare normal hematopoietic precursor cells. Here we reasoned that donor autoantibodies from AML recipients cured…
Abstract Background We aimed to study outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients aged above 70 with using post-transplant cyclophosphamide (PTCy) graft-versus-host disease (GVHD)…
Abstract Venetoclax (VEN) combined with azacitidine (AZA) or low-dose cytarabine (LDAC) has significantly improved outcomes for older patients with acute myeloid leukemia (AML). However, severe cytopenia often leads to treatment interruptions. Previous literature has reported…
Key Points Timely manufacture of VCAR33, a donor-derived CD33-directed CAR T, was feasible in patients with relapsed/refractory AML after alloHCT. VCAR33 had an acceptable safety profile at doses up to 3 × 106 cells/kg and demonstrated antileukemic activity with a response rate…
Abstract Acute leukemia of ambiguous lineage (ALAL) is a rare, high-risk form of acute leukemia. It is characterized by the inability to assign a single lineage of differentiation to the leukemia and can manifest with more than one lineage-defining marker, called mixed phenotype…
Key Points: Many patients and caregivers associate early palliative care (EPC) with hospice or death, a misperception that may persist even after gaining a better understanding of the role of EPC and may prevent them from experiencing the benefits of EPC. Cultural or religious…
Abstract Chimeric antigen receptor (CAR)-T cell therapy has transformed the treatment of hematologic malignancies, yet its application to acute myeloid leukemia (AML) remains challenging due to the scarcity of disease-specific antigens. The identification of a highly selective…
Key Takeaways Approval targets older/unfit newly diagnosed AML, introducing an all-oral HMA/venetoclax backbone that may reduce infusion burden and expand outpatient feasibility. ASCERTAIN‑V part B delivered DEC‑C days 1–5 q28d with venetoclax ramp-up to 400 mg then 400 mg daily…
Abstract Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). While genetic alterations can contribute to resistance, the role of rapid-adaptive non-genetic mechanisms, particularly transcription…